OSU6162 as add-on in SSRI/SNRI-resistant Depression (ODEN): a Double-blind, Placebo-controlled Evaluation of Efficacy and Safety
Latest Information Update: 06 Jul 2024
At a glance
- Drugs OSU 6162 (Primary)
- Indications Depressive disorders
- Focus Therapeutic Use
- Acronyms ODEN
- 02 Oct 2023 Planned number of patients changed from 72 to 180.
- 09 Dec 2022 New trial record